Stelis Biopharma

Bengaluru, India Founded: 2013 • Age: 13 yrs Listed Acquired By Strides Pharma Science
Offers contract development and manufacturing for drug products globally.
Request Access
Report Incorrect Data
Page last updated

About Stelis Biopharma

Stelis Biopharma is a publicly listed company based in Bengaluru (India) founded in 2013 by Sohang Chatterjee, and was acquired by Strides Pharma Science in September 2019. It offers contract development and manufacturing for drug products globally. It operates on a B2B model. Stelis Biopharma has raised $201.78 million across 8 funding rounds from investors including Strides Pharma Science, Accel and TPG. The company has 556 employees. Stelis Biopharma was last valued at $265.41 million in March 2021. Its Indian entity Onesource Specialty Pharma Limited reported revenue of ₹1,437 Cr. Stelis Biopharma offers products and services including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules. Its focus areas include Pharmaceuticals, Manufacturing, CDMO and Biotechnology.

Company details

OneSource is a CDMO specializing in pharmaceuticals and biologics, providing end-to-end services from concept to delivery. They operate state-of-the-art facilities in India, focusing on development, manufacturing, and compliance for various modalities like injectables and capsules. With expertise in regulatory approvals and tech transfer, they serve clients in the healthcare sector to transform ideas into market-ready products.

Operational Areas
Healthcare → Pharmaceuticals & Distribution
Healthcare → Clinical Trials & Research Tech
Key Metrics
  • Market Cap
    ₹17,924 Cr

    ONESOURCE · NSE

  • Share Price
    ₹1,584.50

    +1.38% today

  • Revenue
    ₹1,422 Cr

    FY 2025-26 · -1.6% YoY

  • EBITDA
    ₹294 Cr

    Margin 20.7%

  • Net Profit
    −₹64.12 Cr

    FY 2025-26 · -161.1% YoY

  • Debt / Equity
    0.17

    Interest cover 803.9x

  • Total Equity Funding
    $201.78M (USD)

    in 8 rounds

  • Latest Funding Round
    $125M (USD), Series C

    Mar 2021

  • Investors
    Strides Pharma Science

    & 13 more

  • Employee Count
    556
  • Acquired by
    Strides Pharma Science

    (Sep 2019)

Products & Services of Stelis Biopharma

Stelis Biopharma offers a comprehensive portfolio of products and services, including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules.

Drug-Device Combinations
Manufacturing

Assembly of drug-device products for pharmaceutical applications.

Sterile Injectables
Production

Development and manufacturing of complex injectable drugs.

Complex Biologics
Biotech Services

Integrated solutions for biologics process and scale-up.

Soft Gelatin Capsules
Formulation

Production of high-quality capsules in various formats.

Funding Insights of Stelis Biopharma

Stelis Biopharma has successfully raised a total of $201.78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $201.78M
  • Total Rounds 8
  • Last Round Series C — $125M
  • First Round $507,480

    (Dec 2007)

  • Investors Count 14

All 8 funding rounds of Stelis Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$125MSeries C$265.41MTPG
RouteOne, Think Investments
Nov 2018$42.91MSeries B$93.19MTenshi Life Sciences
GMS Holdings
Feb 2016$31.15MSeries B–GMS Holdings
Tenshi Life Sciences
Jan 2015$1.32MSeries A–Strides Pharma Science
–
Jul 2010$167,265Angel Round$•••••Menaka R Gubbi
B K Iyer, Tanya Julka
Jun 2009$523,986Seed$•••••Accel
–
Dec 2008$200,090Seed$•••••Erasmic Venture Fund
–
Dec 2007$507,480Seed$•••••Erasmic Venture Fund
–
Valuation history
DateValuationStage
Mar 2021$265.41M••••••••
Nov 2018$93.19M••••••••
Jul 2010$•••••••••••••
Jun 2009$•••••••••••••
Dec 2008$•••••••••••••
Dec 2007$•••••••••••••
Premium access

Full valuation and stage history of Stelis Biopharma

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $265.41M (Mar 2021). 14 investors in total: 10 institutional and 4 angel.

Investors in Stelis Biopharma

Stelis Biopharma has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Strides Pharma Science, Accel and TPG.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
TPG
Fund of funds focused on pre-seed and seed-stage companies
1992tpg.comFort Worth, United States
Think Investments
Investment Firm
thinkinvestments.comSan Francisco, United States
GMS Holdings
gmsholdings.com
Timf Holdings
Venture capital is focused on auto tech and multiple sectors.
San Francisco, United States
Accel
Accel is recognized as a leading venture capital firm.
1983accel.comPalo Alto, United States
RouteOne
Web-based credit applications are managed for automotive dealerships.
2002routeone.comDetroit, United States
Medella Holdings
Tenshi Life Sciences
Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems.
2007tenshi.co.inBengaluru, India
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990strides.comBengaluru, India
Erasmic Venture Fund
Limited information available
2003erasmic.comBengaluru, India
Premium access

Investor details for Stelis Biopharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Onesource Specialty Pharma Limited (Stelis Biopharma)

Onesource Specialty Pharma Limited is the primary company behind Stelis Biopharma. The boards of the 2 registered companies of Stelis Biopharma currently have 10 directors; the longest-serving is Sudhir Krishna Kanchan, appointed in 2012. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sudhir Krishna Kanchan
DIN 01606191
Director16 May 201214 yrs 5 moStelis Biopharma Private Limited
Joe Thomas Mangalam
DIN 00468077
Additional Director06 Mar 201412 yrs 7 moStelis Biopharma Private Limited
Arun Kumar Pillai
DIN 00084845
Director07 Apr 20215 yrs 6 moOnesource Specialty Pharma Limited
Neeraj Sharma
DIN 09402652
Managing Director01 Mar 20242 yrs 8 moOnesource Specialty Pharma Limited
Rashmi Harshadrai Barbhaiya
DIN 10593871
Director17 May 20242 yrs 5 moOnesource Specialty Pharma Limited
Bharat Dhirajlal Shah
DIN 00136969
Director26 Jul 20242 yrs 3 moOnesource Specialty Pharma Limited
Debarati Sen
DIN 07521172
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Claudio Dr Albrecht
DIN 10109819
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Vijay Paul Karwal
DIN 10905781
Director27 Feb 20251 yr 8 moOnesource Specialty Pharma Limited
Colin Bond Michael
DIN 10982819
Director23 Jun 20251 yr 4 moOnesource Specialty Pharma Limited

People of Stelis Biopharma

31 people are tracked at Stelis Biopharma (9 in leadership, 9 in board & advisors, 13 in team); the tracked headcount is 556.

NameRoleGroup
Sohang Chatterjee
Co-FounderLeadership
Mark W. Womack
CEO & Managing DirectorLeadership
Kannan Pudhucode
CFO & Executive DirectorLeadership
Kiran Kumar
Director Human ResourcesLeadership
Frank Ternes
Chief Business OfficerLeadership
Manish Sharma
General ManagerLeadership
Vijaykumar H R
Site - HR Business PartnerLeadership
Abhay Desai
Deputy General ManagerLeadership
Vibin Varghese
General ManagerLeadership
Deepak Vaidya
DirectorBoard & advisors
Yogita Hatangadi
DirectorBoard & advisors
Gopakumar Nair
DirectorBoard & advisors
Rajashri Ojha
DirectorBoard & advisors
Aditya Puri
ChairpersonBoard & advisors
Vineeta Rai
DirectorBoard & advisors
Arun Kumar
Founder & DirectorBoard & advisors
Mahaevan Naravanamoni
DirectorBoard & advisors
Ankur Thadani
DirectorBoard & advisors
Ranjana Satish
Human Resources ManagerTeam
Kumar Kiran
Senior Manager HRTeam

11 more people are available in the full profile.

Premium access

Complete people profiles for Stelis Biopharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Stelis Biopharma

Stelis Biopharma is a publicly listed company on the NSE with ticker symbol ONESOURCE in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: ONESOURCE
  • Listed entityOnesource Specialty Pharma Limited
  • Exchange sectorPharmaceuticals

Financials of Stelis Biopharma

Exchange-reported figures of Onesource Specialty Pharma Limited, the listed company behind Stelis Biopharma (NSE: ONESOURCE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,422 Cr
-1.6% YoY
EBITDA
₹294 Cr
-17.1% YoY
Profit After Tax
−₹64.12 Cr
-161.1% YoY
Net Worth
₹5,831 Cr
-0.8% YoY
Total Assets
₹7,346 Cr
+7.5% YoY
Total Debt
₹1,276 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Balance sheet
Total assets7,3466,8349691,6522,1911,173
Net worth5,8315,8813967851,012776
Total debt1,2767725628641,154386
Cash & bank97.5730160.3379.8317077.77
Net working capital691516(179)(133)25914.20
Cash flow
Cash from operations8.52(67.85)(107)(163)(416)(118)
Cash from investing(495)(201)511(67.72)(692)(207)
Cash from financing359412(391)1181,162381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Profit before tax21.20(22.14)(390)(799)(230)(121)
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Balance sheet
Total assets7,4746,8819711,6532,1941,176
Net worth5,9505,9203987871,016779
Total debt1,5049425718641,154386
Cash & bank89.9522860.2579.7616977.41
Net working capital649505(177)(132)26012.03
Cash flow
Cash from operations55.18(47.28)(109)(165)(420)(115)
Cash from investing(478)(300)506(65.68)(685)(210)
Cash from financing361417(384)1181,159381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
Other income15.0217.474.232.693.771.01
Total expenses1,1271,09040272822992.74
Employee cost0.0021579.3672.8060.9935.60
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Depreciation27927476.2965.6870.3534.40
Interest12216689.4547.5568.0315.82
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Tax(18.16)(49.79)0.000.00(0.11)0.27
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.041.54
Reserves & surplus5,8195,8693927811,009774
Shareholders' funds (net worth)5,8315,8813967851,012776
Minority interest0.000.000.000.000.000.00
Secured loans1,140658137433597309
Unsecured loans13611442543155776.59
Total debt1,2767725628641,154386
Total liabilities7,3466,8349691,6522,1911,173
Assets
Gross block6,7996,6441,1391,6331,391718
Net block6,0176,1188631,3611,231633
Capital work in progress529218188334490431
Investments15.6815.7919.584.500.000.00
Inventories5332651281392754.89
Sundry debtors69041755.243.8223.642.22
Cash & bank balances97.5730160.3379.8317077.77
Loans & advances19420233.797.1042.2413.83
Total current assets1,5151,18427823051198.71
Total current liabilities82466845736325284.51
Net working capital691516(179)(133)25914.20
Total assets7,3466,8349691,6522,1911,173
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16522.269.4712267.2911.28
Net cash from operating activities8.52(67.85)(107)(163)(416)(118)
Net cash from investing activities(495)(201)511(67.72)(692)(207)
Net cash from financing activities359412(391)1181,162381
Net change in cash(127)14312.79(112)54.4756.01
Closing cash97.5730160.3379.8317077.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA growth-17.1%+254.6%+66.7%-613.1%-35.5%-
PBT growth-35.8%+82.7%+51.1%-245.9%-91.8%+9997.0%
Net income growth-161.1%+139.0%+59.0%-181.9%-92.7%-
Revenue CAGR (3Y)+232.4%+122.0%+100.3%---
EBITDA CAGR (3Y)--+47.7%---
Profitability & leverage
Net income margin-5.2%-1.2%-227.5%-2066.2%-175.0%-564.9%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.170.211.211.120.860.72
Long-term debt / equity0.070.080.530.530.510.56
Interest cover803.88205.08-29.24-6.30-40.73-14.96
Efficiency & per share
Fixed asset turnover0.210.370.120.030.130.04
Inventory turnover3.567.351.290.190.948.75
Debtors turnover2.576.125.822.8210.2219.18
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)508.70513.9098.68195.87333.495,029.28
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
Other income15.0127.658.752.705.861.01
Total expenses1,1421,05340568422993.43
Employee cost24021579.3672.8056.9731.22
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Depreciation13713576.2910970.3534.40
Interest12116289.4247.5568.0215.80
Profit before tax21.20(22.14)(390)(799)(230)(121)
Tax0.00(41.46)0.000.000.000.00
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.911.54
Reserves & surplus5,9385,9093947831,012777
Shareholders' funds (net worth)5,9505,9203987871,016779
Secured loans1,1406581373831,154309
Unsecured loans3642854344810.0076.59
Total debt1,5049425718641,154386
Total liabilities7,4746,8819711,6532,1941,176
Assets
Gross block3,6973,5871,1391,6331,392718
Net block3,1983,2008631,3611,231633
Capital work in progress469206188334440382
Investments2,9312,84819.704.5151.6753.19
Inventories5332601281392634.89
Sundry debtors73544255.413.7436.602.24
Cash & bank balances89.9522860.2579.7616977.41
Loans & advances18719233.747.0543.0713.83
Total current assets1,5461,12227823051298.37
Total current liabilities89761645536125186.34
Net working capital649505(177)(132)26012.03
Total assets7,4746,8819711,6532,1941,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash92.0922.199.4112166.9211.17
Net cash from operating activities55.18(47.28)(109)(165)(420)(115)
Net cash from investing activities(478)(300)506(65.68)(685)(210)
Net cash from financing activities361417(384)1181,159381
Net change in cash(61.37)69.9012.78(112)54.5555.76
Closing cash89.9522860.2579.7616977.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA growth+7.0%+205.5%+63.8%-563.8%-35.0%-
PBT growth+9998.0%+94.3%+51.2%-247.8%-89.5%+9997.0%
Net income growth-79.7%+148.5%+58.0%-179.2%-89.6%-
Revenue CAGR (3Y)+231.1%+114.3%+100.3%---
EBITDA CAGR (3Y)--+48.0%---
Profitability & leverage
Net income margin+1.5%+1.5%-227.1%-2064.4%-173.9%-566.8%
Return on capital employed+1.6%+5.2%0.0%0.0%0.0%0.0%
Return on net worth+0.3%+3.2%0.0%0.0%0.0%0.0%
Debt / equity0.210.241.211.120.860.72
Long-term debt / equity0.100.100.540.530.510.56
Interest cover95.12144.51-28.87-6.30-40.59-14.84
Efficiency & per share
Fixed asset turnover0.390.550.120.030.130.04
Inventory turnover3.546.691.290.190.998.75
Debtors turnover2.395.235.811.926.8019.01
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)519.07517.3699.191,961.88259.755,045.70

Timeline of Stelis Biopharma

5 dated milestones of Stelis Biopharma across 14 years, from founding to its latest funding, stage changes and deals.

  1. Funding First funding round of $507K.
  2. Milestone Reaches Minicorn status.
  3. Founded Stelis Biopharma is founded.
  4. Exit Acquired by Strides Pharma Science.
  5. Funding Latest funding round, Series C, of $125.0M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Stelis Biopharma

ONESOURCE: Gets USFDA EIR With VAI Status, Finishing Inspection At Bengaluru's Sterile Product Division Facility.
Exchange Update • 3 days ago
ONESOURCE: Q2 SL NET PROFIT 862M RUPEES VS 371M (YOY)
Exchange Update • 6 days ago
ONESOURCE: Q2 REVENUE 5.14B RUPEES VS 3.76B (YOY)
Exchange Update • 6 days ago
ONESOURCE: Q2 EBITDA 1.58B RUPEES VS 1B (YOY); Q2 EBITDA MARGIN 30.8% VS 27.07% (YOY)
Exchange Update • 6 days ago
Onesource Specialty: Expects Semaglutide Approvals In Brazil And Turkey Within The Next 2 Quarters.
Exchange Update • 6 days ago
Top Gainers & Losers on 3 August: Urban Company, Pine Labs, Redington, Paytm, TCS, Meesho among top gainers
Mint • 3 months ago
Buy Onesource Specialty Pharma; target of Rs 2400: ICICI Securities
Moneycontrol • 3 months ago
ONESOURCE: Q1FY27 delivered strong growth, with semaglutide and biologics driving revenue and margin gains
Quartr • 3 months ago
ONESOURCE: Q1 revenue and EBITDA surged on strong demand, capacity expansion, and robust outlook
Quartr • 3 months ago
ONESOURCE: Strong revenue growth and profitability rebound, despite ongoing legal dispute
Quartr • 3 months ago
Premium access

Complete news archive for Stelis Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Stelis Biopharma

Stelis Biopharma was founded in 2013.

Stelis Biopharma is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Stelis Biopharma is a funded company, having raised a total of $201.78M across 8 funding rounds to date. The company's 1st funding round was a Seed of $507.48K, raised on Dec 2007.

Stelis Biopharma has 556 employees.

The primary company behind Stelis Biopharma, Onesource Specialty Pharma Limited, reported revenue of ₹1,437 Cr for FY 2026, down 2% year on year.

OneSource is a CDMO specializing in pharmaceuticals and biologics, providing end-to-end services from concept to delivery. They operate state-of-the-art facilities in India, focusing on development, manufacturing, and compliance for various modalities like injectables and capsules. With expertise in regulatory approvals and tech transfer, they serve clients in the healthcare sector to transform ideas into market-ready products.

Stelis Biopharma offers Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules.

Yes, Stelis Biopharma is publicly traded on NSE under the ticker symbol ONESOURCE.

Stelis Biopharma has 14 investors. Key investors include Strides Pharma Science, Accel, TPG, RouteOne, and Tenshi Life Sciences.

The valuation of Stelis Biopharma is $265.41M as of Mar 2021.

Stelis Biopharma is associated with 2 legal entities: Onesource Specialty Pharma Limited, Stelis Biopharma Private Limited.

Yes. Stelis Biopharma was acquired by Strides Pharma Science in September 2019.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available